Patents Issued in November 6, 2003
  • Publication number: 20030206892
    Abstract: A method of modulating the activity of a Haemophilus influenzae DXR reductoisomerase enzyme, involving contacting a DXR reductoisomerase enzyme with a compound that inhibits non-mevalonate isoprenoid biosynthesis by lowering or preventing the biosynthesis of either menaquinone or ubiquinone. Pharmaceutical compositions containing such compounds may be used to treat infections. Also provided are methods for utilizing DXR polypeptides and polynucleotides to screen for antibacterial compounds.
    Type: Application
    Filed: August 9, 2001
    Publication date: November 6, 2003
    Inventors: Deborah Dee Jaworski, David J. Payne, Courtney E. Slater-Radosti, Kang Yan
  • Publication number: 20030206893
    Abstract: Pharmaceutical compositions and methods of using the same are provided utilizing effective amounts of one or more plant growth factors, gibberellic acid, kinetin, zeatin and jasmonic acid to increase cell proliferation in various tissues and cell lines. As examples, the compositions and methods of the present invention can be used to increase proliferation of fibroblast cells and, more particularly, in the treatment of wounds as well as strengthening of the skin.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 6, 2003
    Inventor: Sohail Malik
  • Publication number: 20030206894
    Abstract: The invention provides a continuous flow apparatus and method for purifying charged substances from solutions or suspensions by isoelectric focusing on an industrial scale.
    Type: Application
    Filed: June 2, 2003
    Publication date: November 6, 2003
    Applicant: CERBERUS ENTERPRISES B.V.
    Inventors: Gerben De Boer, Oto Sova
  • Publication number: 20030206895
    Abstract: A composition is disclosed which comprises as characterizing active ingredients propionyl L-carnitine and a flavonoid, typically quercetin or its 3-rutinoside, rutin, for the prevention and/or therapeutic treatment of various alterations and pathological states induced by free radicals and by thrombotic or atherosclerotic abnormalities, that may take the form of a dietary supplement, dietetic support or of an actual medicine.
    Type: Application
    Filed: June 4, 2003
    Publication date: November 6, 2003
    Applicant: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Publication number: 20030206896
    Abstract: A cosmetic method for providing improved skin hydration is provided comprising the steps of topically applying to the skin a protease enzyme, and simultaneously or sequentially, topically applying to the skin a polyhydric alcohol. Also provided is a cosmetic method for providing improved skin hydration comprising topically applying to the skin a polyhydric alcohol, and simultaneously or sequentially, topically applying to the skin a protease enzyme.
    Type: Application
    Filed: March 12, 2003
    Publication date: November 6, 2003
    Inventors: Conor James O'Prey, Marina Trani, David John Weisgerber
  • Publication number: 20030206897
    Abstract: An oil in water emulsion are useful for treating skin or hair comprising:
    Type: Application
    Filed: March 12, 2003
    Publication date: November 6, 2003
    Applicant: The Procter & Gamble Company
    Inventors: Conor James O'Prey, Marina Trani, David John Weisgerber
  • Publication number: 20030206898
    Abstract: The present invention is directed to a method of treating disorders in which TFN&agr; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.
    Type: Application
    Filed: April 26, 2002
    Publication date: November 6, 2003
    Inventors: Steven Fischkoff, Elliot Chartash
  • Publication number: 20030206899
    Abstract: The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases and disorders characterized by undesirable or excessive endothelial cell proliferation or neovascularization. The monoclonal antibodies and receptors of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF in a test sample.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 6, 2003
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • Publication number: 20030206900
    Abstract: The present invention provides novel polypeptides which can effectively penetrate into cells thereby transporting a substance of interest into the cells.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 6, 2003
    Applicants: INSTITUT PASTEUR, Universite Pierre et Marie Curie
    Inventors: Therese Ternynck, Alexandre Avrameas, Gerard Buttin, Stratis Avrameas, Marie-Francoise Saron, Bruno Blondel, Therese Couderc, Susan Michelson, Donato Zipeto
  • Publication number: 20030206901
    Abstract: The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)]expressed on the surface of metastasizing cancer cells.
    Type: Application
    Filed: August 28, 2002
    Publication date: November 6, 2003
    Inventor: Wen-Tien Chen
  • Publication number: 20030206902
    Abstract: The present invention includes the use of an antagonist of vascular endothelial growth factor receptor (VEGFR) in combination with an antagonist of vascular endothelial cadherin (VE-cadherin) to modulate angiogenesis. Included is the use of the VEGFR antagonist and the antagonist of VE-cadherin in a manner so as to prevent or ameliorate toxicity associated with the use of VE-cadherin antagonist. The present invention also comprises the use of a VEGFR antagonist and a VE-cadherin antagonist for treating, with reduced toxicity, diseases associated with angiogenesis, which include but are not limited to neoplastic diseases, autoimmune diseases and collagen vascular diseases, as well as the use of a VEGFR antagonist for the treatment of disease states associated with pathological vascular permeability which include, but are not limited to, ARDS, edema states and related conditions.
    Type: Application
    Filed: January 15, 2003
    Publication date: November 6, 2003
    Inventors: Fang Liao, Daniel Hicklin, Peter Boehlen
  • Publication number: 20030206903
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Application
    Filed: May 19, 2003
    Publication date: November 6, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez
  • Publication number: 20030206904
    Abstract: The present invention relates to a method and therapeutic composition for the treatment of myocardial infarction comprising administration of a tissue factor protein antagonist and a thrombolytic agent.
    Type: Application
    Filed: August 8, 2001
    Publication date: November 6, 2003
    Applicant: Genentech, Inc.
    Inventors: Donogh P. O'Brien, Gordon A. Vehar
  • Publication number: 20030206905
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberranty expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: November 7, 2002
    Publication date: November 6, 2003
    Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid
  • Publication number: 20030206906
    Abstract: A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent.
    Type: Application
    Filed: November 25, 2002
    Publication date: November 6, 2003
    Applicant: GENENTECH, INC.
    Inventor: Charles P. Semba
  • Publication number: 20030206907
    Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
    Type: Application
    Filed: April 9, 2003
    Publication date: November 6, 2003
    Inventor: Scott Koenig
  • Publication number: 20030206908
    Abstract: The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.
    Type: Application
    Filed: September 13, 2002
    Publication date: November 6, 2003
    Inventor: Yaling Zhou
  • Publication number: 20030206909
    Abstract: Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors.
    Type: Application
    Filed: February 7, 2003
    Publication date: November 6, 2003
    Inventors: Shaobing Hua, Michelle Haynes Pauling, Li Zhu
  • Publication number: 20030206910
    Abstract: The invention features selected polymers such as poloxamer 188 (Pluronic® F68), poloxamer 237 (Pluronic® F87), poloxamer 401 (Pluronic® L121), poloxamer 338 (Pluronic® F108), Poloxamer 124 (Pluronic® L44), Poloxamer 184 (L-64), and poloxamines (Tetronics® 904, 908, 1107, and 90R4) that enhance expression from nucleic acids when administered into an organism, in particular to muscle, and further provides selected poloxamer formulations for delivery of nucleic acids to the liver.
    Type: Application
    Filed: September 3, 2002
    Publication date: November 6, 2003
    Inventors: Francois Nicol, Jijun Wang, Michael E. Coleman, Fiona MacLaughlin, Alain Rolland
  • Publication number: 20030206911
    Abstract: A method for enhancing intracellular delivery of effector molecules is provided. The method involves modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target specifically recognized by the antibody.
    Type: Application
    Filed: May 28, 2003
    Publication date: November 6, 2003
    Inventors: Vladimir R. Muzykantov, Steven M. Albelda
  • Publication number: 20030206912
    Abstract: The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartilage- and bone-derived tumors.
    Type: Application
    Filed: December 12, 2002
    Publication date: November 6, 2003
    Applicants: Yeda Research And Development Co., Ltd., Ramot Univ. Authority for applied Research and Industrial Development Ltd., both Israeli Cor.
    Inventors: Avner Yayon, Zvi Nevo
  • Publication number: 20030206913
    Abstract: A method is described for improving the nutritional value of a foodstuff comprising a source of myo-inositol hexakisphosphate by feeding the foodstuff in combination with a phytase expressed in yeast. The method comprises the step of feeding the animal the foodstuff in combination with a phytase expressed in yeast wherein the phytase can be selected from the group consisting of AppA1, AppA2 and a site-directed mutant of AppA. The invention also enables reduction of the feed to weight gain ratio and an increase bone mass and mineral content of an animal. A foodstuff and a feed additive comprising AppA2 or a site-directed mutant of AppA are also described.
    Type: Application
    Filed: October 31, 2002
    Publication date: November 6, 2003
    Inventors: Douglas M. Webel, Donald E. Orr, Frank E. Ruch
  • Publication number: 20030206914
    Abstract: Synthetic antigens which comprise hydrophobic and hydrophilic components are provided for inducing CD1-restricted T cell responses in mammals. Further provided are methods for using these antigens and compositions which are combinations of CD1-recognized synthetic antigens, additional antigens, adjuvants and other substances that induce immune responses.
    Type: Application
    Filed: May 15, 2003
    Publication date: November 6, 2003
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Steven A. Porcelli, D. Branch Moody
  • Publication number: 20030206915
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: October 25, 2001
    Publication date: November 6, 2003
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Publication number: 20030206916
    Abstract: The invention provides relatively short immunogenic peptides, and biologically active variants thereof, associated with leukemia which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer.
    Type: Application
    Filed: May 3, 2002
    Publication date: November 6, 2003
    Applicant: Rush-Presbyterian-St. Luke's Medical Center
    Inventors: Joo-Eun Bae, Hans-G. Klingemann
  • Publication number: 20030206917
    Abstract: Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. In an additional aspect of the invention, methods of making fusion proteins having cis signaling capabilities, as well as the ability to bind with receptors on the cell's own surface, are provided. Fusion proteins incorporating GPI or a homing element, and a costimulator or inhibitor domain can also be directly transferred to the cell surface. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.
    Type: Application
    Filed: July 25, 2002
    Publication date: November 6, 2003
    Inventors: Mark L. Tykocinski, Guoxing Zheng
  • Publication number: 20030206918
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
    Type: Application
    Filed: February 5, 2003
    Publication date: November 6, 2003
    Applicant: Corixa Corporation
    Inventors: Gary R. Fanger, Steven P. Fling
  • Publication number: 20030206919
    Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
    Type: Application
    Filed: November 26, 2002
    Publication date: November 6, 2003
    Inventor: Matti Sallberg
  • Publication number: 20030206920
    Abstract: A protein product extracted from apathogen bacilli is described.
    Type: Application
    Filed: May 2, 2002
    Publication date: November 6, 2003
    Inventor: Rafael Chacon Pabon
  • Publication number: 20030206921
    Abstract: The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding an ATP-binding cassette of a strain of Chlamydia pneumoniae and a promoter to effect expression of the ATP-binding cassette gene product in the host. Modifications are possible within the scope of this invention.
    Type: Application
    Filed: January 7, 2003
    Publication date: November 6, 2003
    Applicant: Aventis Pasteur Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
  • Publication number: 20030206922
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: June 3, 2003
    Publication date: November 6, 2003
    Applicant: Willmar Poultry Company, Inc.
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
  • Publication number: 20030206923
    Abstract: A dietary supplement comprising as its active ingredients soybean, mushroom and mung bean is used in a method to in a method to ameliorate at least one effective malignancy or viral infection or to enhance immune functions. The active components of the dietary supplement include phytoestrogens, &bgr;-glucans, saponins, inositol hexaphosphate, and lectins.
    Type: Application
    Filed: May 28, 2003
    Publication date: November 6, 2003
    Inventor: Alexander Sun
  • Publication number: 20030206924
    Abstract: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.
    Type: Application
    Filed: March 20, 2001
    Publication date: November 6, 2003
    Inventor: Mark W. Mellencamp
  • Publication number: 20030206925
    Abstract: Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.
    Type: Application
    Filed: December 16, 2002
    Publication date: November 6, 2003
    Inventor: Christopher L. Parks
  • Publication number: 20030206926
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. 1 TABLE 1 CEF Hela HaCat 143B BHK Vero CV-1 MVA- 579.73 0.04 0.22 0.00 65.88 2.33 0.00 BN MVA- 796.53 0.15 1.17 0.02 131.22 10.66 0.06 575 MVA- 86.68 124.97 59.09 0.83 87.86 34.97 29.70 HLR MVA- 251.89 27.41 1.28 2.91 702.77 1416.46 4.
    Type: Application
    Filed: May 16, 2003
    Publication date: November 6, 2003
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Publication number: 20030206927
    Abstract: Hemolysin isolated from hemolysin-producing fungi can be used to detect if a human or other animal has been exposed to a hemolysin-producing fungus. The method and proteins of the present invention can be used to screen humans and other animals for exposure to such fungi, as well as to produce vaccines for protecting humans and other animals that may be exposed to such fungi.
    Type: Application
    Filed: May 30, 2001
    Publication date: November 6, 2003
    Inventor: Stephen Joseph Vesper
  • Publication number: 20030206928
    Abstract: The invention relates to bioactive, biocompatible, bioabsorbable surgical composites and devices, such as plates, meshes, membranes, pins, screws, tacks, bolts, intramedullary nails, suture anchors, staples, bone plugs or other devices which are applied in bone-to-bone, soft tissue-to-bone or soft tissue-to-soft tissue fixation or in guided tissue regeneration or in fixation of bioabsorbable and/or biostable implants in, and/or on, bone or soft tissue, which composites and devices are fabricated of bioabsorbable segmented block copolymer of polyethylene glycol and polybutylene terephtalate that contains bioactive ceramic particles or reinforcement fibers and optional porosity.
    Type: Application
    Filed: April 7, 1999
    Publication date: November 6, 2003
    Inventors: PERTTI TORMALA, MINNA KELLOMAKI
  • Publication number: 20030206929
    Abstract: Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD50 of at least 400 mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B in oily vehicle and dispersing emulsifier in the aqueous phase. The process of present invention is simple, cost effective and gives a stable product suitable for parenteral administration. Amphotericin B emulsion compositions prepared by the process of the present invention may be administered to human beings and animals for the treatment of fungal infections, with substantially equivalent or greater efficacy and low drug toxicity as compared to the conventional composition containing Amphotericin B and sodium desoxycholate.
    Type: Application
    Filed: May 30, 2003
    Publication date: November 6, 2003
    Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Korcharekar
  • Publication number: 20030206930
    Abstract: Soft gelatin capsules having a capsule shell comprising gelatin, plasticizers and, if desired or required, further auxiliary agents, and a capsule filling containing a solvent including a migrateable solvent such as 1,2-propyleneglycol as a solvent in the capsule filling and in the capsule shell. The manufacture of said capsules is improved, if in the process for making the soft gelatin capsules the gelatin bands are cooled with a liquid, and preferably with water.
    Type: Application
    Filed: May 13, 2003
    Publication date: November 6, 2003
    Inventors: Werner Brox, Armin Meinzer, Horst Zande
  • Publication number: 20030206931
    Abstract: The present invention includes a clear cosmetic stick that has a clarity that is stable over a temperature of 5 to 45 degrees Centigrade for a time period of at least about twelve months. The clear cosmetic stick includes one or more of a branched chain fatty acid surfactant and a straight-chain fatty alcohol surfactant.
    Type: Application
    Filed: May 1, 2002
    Publication date: November 6, 2003
    Inventors: Bhalchandra Moghe, Thomas Schamper
  • Publication number: 20030206932
    Abstract: Skin care compositions comprising an oil-in-water emulsion base containing retinoids and possessing good physical and chemical stability
    Type: Application
    Filed: August 7, 2002
    Publication date: November 6, 2003
    Inventors: Jue-Chen Liu, Jonas C. T. Wang, Mohammed Yusuf, Norihiro Yamamoto, Satoshi Kazama, Christopher R. Stahl, Jean P. Holland, Kamran Mather, Margaret A. Aleles, Sachio Hamada, Curtis A. Cole, Stephen J. Wisniewski
  • Publication number: 20030206933
    Abstract: There is provided cosmetic agents containing 2-furanone derivatives for the treatment of skin and hair.
    Type: Application
    Filed: November 6, 2002
    Publication date: November 6, 2003
    Inventors: Erik Schulze zur Wiesche, Detlef Hollenberg, Britta Bossmann
  • Publication number: 20030206934
    Abstract: Cosmetic or dermatological preparations in the form of an O/W emulsion comprising
    Type: Application
    Filed: March 7, 2003
    Publication date: November 6, 2003
    Applicant: Beiersdorf AG
    Inventors: Heidi Riedel, Wiebke Lindemann
  • Publication number: 20030206935
    Abstract: The invention relates to novel compounds of formula (I) wherein R1 represents a polymer, aryl or alkyl group. R2 presents a hydrogen atom, a halogen atom, a radical CN, CF3, OH, OCF3, COOH, R7, OR7 or OCOR7, R3 represents an aryl or alkyl halogen, R4 represents an alkyl radical. The invention also relates to a cosmetic composition comprising said compounds and to the use thereof to reduce and/or curb hair loss i.e. to increase and/or stimulate the growth of said hair.
    Type: Application
    Filed: April 4, 2003
    Publication date: November 6, 2003
    Applicant: L'Oreal
    Inventors: Jean-Baptiste Galey, Maria Dalko, Lionel Breton
  • Publication number: 20030206936
    Abstract: A cosmetic composition for topical application to human skin comprising an effective amount of a hydroxy phenyl alkyl carboxylic acid of general formula (I): 1
    Type: Application
    Filed: April 22, 2003
    Publication date: November 6, 2003
    Applicant: Unilever Home & Personal Care USA, Division of Conopco, Inc.
    Inventors: Scott Sinclair Barclay, John Anthony Bosley, Robert Mark Donovan, Alexander Gordon James, Andrew Easson Mayes, Julia Sarah Rogers
  • Publication number: 20030206937
    Abstract: The invention is directed toward a malleable bone putty and a flowable pastel composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of partially demineralized lyophilized allograft bone material having a residual calcium content ranging from 4 to 8% dry weight. The bone powder has a particle size ranging from about 100 to about 800 microns and is mixed in a high molecular weight hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 1.00 to 50% of the composition and having a molecular weight of about at least 700,000 Daltons. The composition has a pH between 6.8-7.4 contains about 25% to about 35% bone powder and can be additionally provided with BMP's.
    Type: Application
    Filed: October 24, 2001
    Publication date: November 6, 2003
    Inventors: Arthur A. Gertzman, Moon H. Sunwoo
  • Publication number: 20030206938
    Abstract: A method for treating ocular conditions such as bacterial keratitis, bacterial conjunctivitis, corneal ulcers and wounds, endophthalmitis, and blebitis in mammals, by using a native, synthetic, or recombinant CAP37, or effective peptide portions thereof including CAP37 peptides 20-44, 23-42, 102-122, and 120-146 and monocysteine derivatives of peptides 20-44 and 23-42. The CAP37, peptides, and peptide derivatives can also be used to store, clean, sterilize, or coat contact lenses, and may be used in media for storing mammalian corneal transplants.
    Type: Application
    Filed: April 25, 2003
    Publication date: November 6, 2003
    Inventors: Heloise Anne Pereira, James Chodosh, Michelle C. Callegan
  • Publication number: 20030206939
    Abstract: The present invention provides a formulation for the delivery of bioactive constituents to biological surfaces, wherein said formulation comprises a suspension or solution of at least one isolated and purified casein protein or salt thereof, in water, together with at least one bioactive constituent.
    Type: Application
    Filed: May 16, 2003
    Publication date: November 6, 2003
    Applicant: Pacific Biolink Pty. Limited
    Inventor: Dennis James Bannister
  • Publication number: 20030206940
    Abstract: A disposable, single-use, personal care article is disclosed having an active zone, an adjacent non-active zone, and interface therebetween; a benefit agent releasably associated with the active zone; a carrier solvent and optionally a visual indicator associated with the active zone. In one embodiment, the benefit agent, the carrier solvent, and a dye indicator are combined and applied as stripes on the article. The stripes will not substantially bleed into the adjacent non-active zone and will disappear during use of the article indicating that the benefit agent has been transferred to the skin or hair of the user.
    Type: Application
    Filed: April 26, 2002
    Publication date: November 6, 2003
    Inventors: Robert Edward Gott, Ewa Padlo, Craig Stephen Slavtcheff
  • Publication number: 20030206941
    Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.
    Type: Application
    Filed: April 17, 2003
    Publication date: November 6, 2003
    Inventors: Sau-Hung Spence Leung, Robert S. Leone, Lori D. Kumar, Neema Kulkarni, Albert F. Sorg